Published in Br J Cancer on July 27, 2010
Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. J Natl Cancer Inst (2015) 1.83
The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men. Eur Urol (2014) 1.57
Tumor markers in prostate cancer I: blood-based markers. Acta Oncol (2011) 1.28
A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev (2010) 1.12
Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer. Curr Opin Urol (2016) 1.00
Emerging PSA-based tests to improve screening. Urol Clin North Am (2014) 0.94
Finding the Wolf in Sheep's Clothing: The 4Kscore Is a Novel Blood Test That Can Accurately Identify the Risk of Aggressive Prostate Cancer. Rev Urol (2015) 0.91
The 4Kscore® Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices. Rev Urol (2015) 0.85
A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort. Eur Urol (2015) 0.82
Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys(₁₄₅) or Lys(₁₄₆) from fPSA without internal cleavages at Lys(₁₄₅) or Lys(₁₄₆). J Immunol Methods (2011) 0.82
Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers. Int J Mol Sci (2016) 0.77
Biomarkers for prostate cancer: present challenges and future opportunities. Future Sci OA (2015) 0.77
Kallikreins as biomarkers for prostate cancer. Biomed Res Int (2014) 0.77
Human kallikrein-2 gene and protein expression predicts prostate cancer at repeat biopsy. Springerplus (2014) 0.77
Novel biomarkers for the detection of prostate cancer. J Clin Urol (2016) 0.77
Potential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate Cancer. Biomed Res Int (2015) 0.76
Detection of High-Grade Prostate Cancer among PLCO Participants Using a Prespecified Four Kallikrein Marker Panel. J Urol (2016) 0.76
Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery. Oncotarget (2017) 0.75
The role of prostate cancer biomarkers in undiagnosed men. Curr Opin Urol (2017) 0.75
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA (2005) 6.50
Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol (2010) 4.15
An updated catalog of prostate cancer predictive tools. Cancer (2008) 2.82
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol (2008) 2.48
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med (2008) 2.47
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med (2008) 2.39
Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol (1994) 2.25
PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology (2007) 2.14
Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men. J Urol (2000) 1.94
Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments. Anal Chem (2006) 1.84
Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol (2001) 1.79
Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. Urology (2000) 1.53
High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol (2006) 1.38
Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int (2003) 1.30
A graphical device to represent the outcomes of a logistic regression analysis. Prostate (2008) 1.25
Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies. J Urol (1997) 1.24
A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res (2010) 1.24
Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure. Urology (2007) 1.18
Validation of a nomogram for predicting positive repeat biopsy for prostate cancer. J Urol (2005) 1.17
Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol (1997) 1.14
A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session. J Urol (2003) 1.08
Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies. Eur Urol (2009) 1.05
Saturation technique does not decrease cancer detection during followup after initial prostate biopsy. J Urol (2008) 1.04
Development and external validation of an extended repeat biopsy nomogram. J Urol (2007) 1.00
Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer. J Urol (1998) 0.99
Predictors of prostate cancer on repeat transrectal ultrasound-guided systematic prostate biopsy. Int J Urol (2003) 0.98
Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels. Urology (1996) 0.96
A novel nomogram to predict the probability of prostate cancer on repeat biopsy. J Urol (2008) 0.92
Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma: who should undergo a repeat biopsy? BJU Int (1999) 0.87
The effect of prostate volume on the yield of needle biopsy. J Urol (1998) 0.84
Prostate cancer detection and tumor characteristics in men with multiple biopsy sessions. Prostate Cancer Prostatic Dis (2004) 0.83
Development and validation of risk score for predicting positive repeat prostate biopsy in patients with a previous negative biopsy in a UK population. BMC Urol (2009) 0.78
A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst (1998) 8.33
Mechanisms of estrogen action. Physiol Rev (2001) 5.97
Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Paediatr (1996) 5.76
Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol (1999) 4.78
Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol (1994) 3.17
Microscopic haematuria. BMJ (1994) 3.00
Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem (1991) 2.96
Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA (1996) 2.74
Cardiotocography only versus cardiotocography plus ST analysis of fetal electrocardiogram for intrapartum fetal monitoring: a Swedish randomised controlled trial. Lancet (2001) 2.68
Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer (2010) 2.45
Factors predicting recovery of erections after radical prostatectomy. J Urol (2000) 2.44
Risk factors for urinary incontinence after radical prostatectomy. J Urol (1996) 2.42
Prostate cancer: to screen or not to screen? BMJ (1993) 2.41
Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. J Clin Oncol (2001) 2.33
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol (2007) 2.26
Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol (1995) 2.19
A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest (1985) 2.04
Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol (1999) 2.00
Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem (1995) 1.98
Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res (1998) 1.95
Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem (1990) 1.95
Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol (1994) 1.94
Two loci on chromosomes 2 and X for premature coronary heart disease identified in early- and late-settlement populations of Finland. Am J Hum Genet (2000) 1.93
Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol (1993) 1.91
Vesicovaginal and ureterovaginal fistulas: a summary of 25 years of experience. J Urol (1980) 1.84
Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol (2000) 1.80
Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology (2001) 1.76
Molecular cloning of human prostate specific antigen cDNA. FEBS Lett (1987) 1.74
The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol (1997) 1.67
Adrenal glands of mouse and rat do not synthesize androgens. Life Sci (1992) 1.64
Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels. J Urol (1995) 1.63
Pathologic features of prostate cancer found at population-based screening with a four-year interval. J Natl Cancer Inst (2001) 1.63
Lethal autosomal recessive syndrome with intrauterine growth retardation, intra- and extrahepatic biliary atresia, and esophageal and duodenal atresia. Am J Med Genet (1998) 1.61
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int (2010) 1.60
Cutaneous metastasis following laparoscopic pelvic lymphadenectomy for prostatic carcinoma. J Urol (1995) 1.59
Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer (2009) 1.59
Transcriptional targets shared by estrogen receptor- related receptors (ERRs) and estrogen receptor (ER) alpha, but not by ERbeta. EMBO J (1999) 1.58
Number-needed-to-treat and placebo-controlled trials. Lancet (1998) 1.56
Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest (1987) 1.55
Pathological features and prognostic significance of prostate cancer in the apical section determined by whole mount histology. J Urol (1999) 1.54
Degradation of cardiac troponin I: implication for reliable immunodetection. Clin Chem (1998) 1.54
Testicular metastasis as the first manifestation of colon carcinoma. J Urol (1988) 1.54
A supersensitive immunofluorometric assay for rat luteinizing hormone. Endocrinology (1993) 1.53
Future prospects in prostate cancer. Prostate (1999) 1.53
The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol (1994) 1.53
Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology (1994) 1.52
Possible mechanism for seeding of tumor during radical prostatectomy. J Urol (1993) 1.52
A catalog of prostate cancer nomograms. J Urol (2001) 1.51
Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res (1997) 1.51
Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up. Br J Cancer (2006) 1.51
Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer (1997) 1.50
Measurement of circulating forms of prostate-specific antigen in whole blood immediately after venipuncture: implications for point-of-care testing. Clin Chem (2001) 1.49
Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology (1994) 1.48
Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology (2000) 1.44
The high prevalence of antiphospholipid antibodies in refractory focal epilepsy is related to recurrent seizures. Eur J Neurol (2008) 1.44
The risk of distant metastases after transurethral resection of the prostate versus needle biopsy in patients with localized prostate cancer. J Urol (1989) 1.43
Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology (1997) 1.41
Screening for prostate cancer--more questions than answers. Acta Oncol (1998) 1.40
One-step all-in-one dry reagent immunoassays with fluorescent europium chelate label and time-resolved fluorometry. Clin Chem (1996) 1.40
A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate. J Urol (1991) 1.40
Errors in transrectal ultrasonic planimetry of the prostate: computer simulation of volumetric errors applied to a screening population. Ultrasound Med Biol (1995) 1.39
Treatment of benign prostatic hyperplasia by transurethral ultrasound-guided laser-induced prostatectomy (TULIP): effects on urodynamic parameters and symptoms. Urology (1994) 1.39
[Diagnosis based on prostate needle biopsy: inadequate correlation between pathologic results and clinical course for individual prognosis]. Ned Tijdschr Geneeskd (2005) 1.37
Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst (1998) 1.36
Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn(2+), a tight-binding inhibitor. Prostate (2000) 1.34
Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol (2000) 1.33
European Randomized Study of Screening for Prostate Cancer: achievements and presentation. BJU Int (2003) 1.32
Detection of prostate cancer. BMJ (1995) 1.30
Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int (2003) 1.30
The human cationic antimicrobial protein (hCAP-18) is expressed in the epithelium of human epididymis, is present in seminal plasma at high concentrations, and is attached to spermatozoa. Infect Immun (2000) 1.30
Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol (1996) 1.29
Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res (1998) 1.28
In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. Urology (1996) 1.27
In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther (1999) 1.26
Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol (1996) 1.26
Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol (1998) 1.26
Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology (1995) 1.25
Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial. J Urol (1997) 1.25
Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate (1988) 1.25
Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM). Urology (2004) 1.25
Has there been a recent shift in the pathological features and prognosis of patients treated with radical prostatectomy? J Urol (1997) 1.24
Functional differences between the amino-terminal domains of estrogen receptors alpha and beta. Mol Pharmacol (2000) 1.24
Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology (1993) 1.23
Modalities available for screening for prostate cancer. Eur J Cancer (1993) 1.23
The value of serum tumor markers in the staging and prognosis of germ cell tumors of the testis. J Urol (1977) 1.23
The association of benign prostatic hyperplasia and cancer of the prostate. Cancer (1992) 1.22
Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res (1995) 1.22
Prognostic significance of the diameter of perineural invasion in radical prostatectomy specimens. Hum Pathol (2001) 1.22
Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun (1997) 1.22